Cidara Therapeutics Company Profile (NASDAQ:CDTX)

Cidara Therapeutics trades on the NASDAQ under the ticker symbol "CDTX."

Cidara Therapeutics, Inc. (NASDAQ:CDTX) issued its earnings results on Wednesday, August, 9th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.91) by $0.08. View Cidara Therapeutics' Earnings History.

10 brokerages have issued 1 year price targets for Cidara Therapeutics' stock. Their forecasts range from $7.25 to $20.00. On average, they expect Cidara Therapeutics' share price to reach $13.65 in the next twelve months. View Analyst Ratings for Cidara Therapeutics.

Here are some recent quotes from research analysts about Cidara Therapeutics stock:

• 1. According to Zacks Investment Research, "Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company developed its product using Cloudbreak(TM) immunotherapy platform. Cidara Therapeutics, Inc. is headquartered in San Diego, California. " (8/14/2017)
• 2. Needham & Company LLC analysts commented, "Cidara mgmt provided a corporate update at an Investor Day in NYC last week and we separately hosted a series of mtgs w/ investors. Mgmt reiterated guidance for top-line results from ongoing Phase 2 trial of CD101 in Invasive Candida infections in 4Q17. The trial is expected to serve as the first of two registration trials. Given discontinuation of CD101 Vulvovaginal Candidiasis program, mgmt introduced plans to instead accelerate development in antifungal prophylaxis. KOLs highlighted differentiation from other echinocandins, w/ emphasis on PK/PD profile and opportunity for better clinical outcomes. New details around Cloudbreak candidates were also announced, although clinical testing not expected until 2018. Stock is attractive ahead of Phase 2 CD101 results later this year (EV $15M)." (4/10/2017)
• 3. Cantor Fitzgerald analysts commented, "PD/PK Data Points to Success in Phase 2: Presentations reviewed the potency of CD101 against Candida and Aspergillus species as well as broad and sustained tissue distribution. We found the PK/PD optimized dosing data persuasive as it clearly demonstrates, effective AUC/MIC levels at the 400mg once-weekly over three weeks and 400mg loading dose followed by 200mg once weekly for two weeks, paralleling the two dosing regimens being studied in the Phase 2. We also note the potential for subcutaneous dosing, which could enhance the commercial story. We have increased our probability of success from 45% to 50%. Breadth of Cloudbreak Platform Highlighted: In addition to the antibacterial CD201, currently working through pre-IND studies, early in vivo/in vitro data was presented on a new antifungal asset." (4/7/2017)

Cidara Therapeutics saw a decline in short interest during the month of August. As of August 15th, there was short interest totalling 536,961 shares, a decline of 53.3% from the July 31st total of 1,149,372 shares. Based on an average daily trading volume, of 109,766 shares, the short-interest ratio is currently 4.9 days. Currently, 5.6% of the shares of the company are short sold.

Some companies that are related to Cidara Therapeutics include Kura Oncology (KURA), Circassia Pharmaceuticals PLC (CIR), Chimerix (CMRX), Pieris Pharmaceuticals (PIRS), Tocagen (TOCA), Mast Therapeutics (SVRA), Faron Pharmaceuticals Oy (FARN), ObsEva SA (OBSV), Ovid Therapeutc (OVID), MannKind Corporation (MNKD), OncoCyte Corp (OCX), Vital Therapies (VTL), Clearside Biomedical (CLSD), Catalyst Pharmaceuticals (CPRX), Kindred Biosciences (KIN), Foamix Pharmaceuticals (FOMX), Zymeworks (ZYME) and Cascadian Therapeutics (CASC).

Cidara Therapeutics' management team includes the folowing people:

• Scott M. Rocklage Ph.D., Chairman of the Board
• Jeffrey Stein Ph.D., President, Chief Executive Officer, Director
• Matthew W. Onaitis J.D., Chief Financial Officer, Principal Financial Officer, General Counsel, Secretary
• Kenneth Bartizal Ph.D., Chief Development Officer
• Paul Daruwala, Chief Commercial Officer
• Kevin M. Forrest Ph.D., Chief Strategy Officer
• Taylor Sandison M.D., Chief Medical Officer
• Daniel D. Burgess, Director
• Timothy R. Franson M.D., Director
• Robert J. Perez, Director

(CDTX) raised $60 million in an IPO on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow Life Sciences, Needham and BTIG were co-managers.

Cidara Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (8.76%), InterWest Venture Management Co (8.07%), Frazier Management LLC (7.78%), BB Biotech AG (6.56%), BROADFIN CAPITAL, LLC (5.28%) and Broadfin Capital LLC (4.84%). Company insiders that own Cidara Therapeutics stock include Jeffrey Stein, Kevin Forrest and Taylor Sandison. View Institutional Ownership Trends for Cidara Therapeutics.

Cidara Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Northern Trust Corp, Vanguard Group Inc. and JPMorgan Chase & Co.. View Insider Buying and Selling for Cidara Therapeutics.

Cidara Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, Goldman Sachs Group Inc., BB Biotech AG, Susquehanna International Group LLP, Trellus Management Company LLC, LMR Partners LLP, Raymond James Financial Services Advisors Inc. and Citadel Advisors LLC. Company insiders that have bought Cidara Therapeutics stock in the last two years include Jeffrey Stein, Kevin Forrest and Taylor Sandison. View Insider Buying and Selling for Cidara Therapeutics.

Shares of Cidara Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Cidara Therapeutics stock can currently be purchased for approximately $7.60.